ClinicalTrials.gg
RecruitingNCT07677410AWATARUpdated Aug 10, 2026

Aspirin Monotherapy Versus Sequential Warfarin-Aspirin Therapy After TAVR in Patients With Pure Aortic Regurgitation

An interventional study of Aspirin and Warfarin in Aortic Regurgitation Disease, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.

Planned enrollment
2nd of 11
1,172 · median 116
Started
2026
with 4 others
No phase
10 of 23
7 open now
Primary completion
2029-07
later than 12 of 16 live
Registered
21st of 23
by date
Lead sponsor
2 of 23
Shanghai Zhongshan Hospital

Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 21st registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Aortic Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

This multicenter randomized controlled trial evaluates antithrombotic strategies post-TAVR in severe aortic regurgitation patients without long-term anticoagulation. Patients are randomized 1:1 to aspirin 75-100 mg daily for 12 months versus warfarin (INR 2-3) for 6 months followed by aspirin for 6 months. Primary hypothesis: aspirin is superior for bleeding and non-inferior for death/thrombosis. Primary endpoint is a composite of death, stroke, thrombosis, MI, embolism, and major bleeding at 1 year. Sample size: 1172. Follow-up: 30 days, 6 months, 12 months.

03

Conditions studied

  • Aortic Regurgitation Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Patients with severe aortic regurgitation (AR) who achieve technical success after TAVR using devices specifically indicated for AR (per VARC-3 criteria).
  • Trileaflet aortic valve anatomy.
  • No long-term anticoagulation indication (including but not limited to: atrial fibrillation, mechanical mitral valve prosthesis, deep vein thrombosis, pulmonary embolism, left ventricular thrombus, pulmonary hypertension, or coagulation disorders) as confirmed by the investigator.
  • Signed written and willingness to comply with randomization, study procedures, and follow-up.

Exclusion criteria

Exclusion Criteria:

  • Need for oral anticoagulation or dual antiplatelet therapy, or need for oral or intravenous strong inhibitors that cannot be paused during the study period.
  • Active pathological bleeding, subdural hematoma, or history of intracranial hemorrhage.
  • Ischemic stroke within 30 days before TAVR.
  • Acute myocardial infarction within 30 days.
  • Severe hepatic insufficiency (cirrhosis, hepatic decompensation).
  • Severe renal insufficiency ( \< 30 mL/min/1.73 m²) or need for renal replacement therapy.
  • Stent implantation (including coronary, carotid, or peripheral arteries) within 12 months before TAVR, or planned stent implantation within 1 year after TAVR.
  • Coronary artery bypass grafting (CABG) within 12 months before TAVR.
  • Allergy, intolerance, or known resistance to aspirin, clopidogrel, or warfarin.
  • Known coagulation disorders or bleeding diathesis (including but not limited to count ≤50,000/mm³ at screening).
  • Any to anticoagulation therapy.
  • Prior aortic valve prosthesis (mechanical or bioprosthetic); mitral valve bioprosthesis replacement within 1 year before TAVR; or prior mitral mechanical valve replacement; or prior tricuspid valve replacement.
  • Emergency TAVR with cardiogenic shock manifesting as low cardiac output, vasopressor or respiratory dependence, or mechanical hemodynamic support.
  • \<1 year (e.g., terminal ).
  • Participation in another drug or device clinical study (patients who have completed the primary endpoint of the study and are currently in long-term follow-up are not excluded).
  • Pregnancy or planned pregnancy, or use of estrogen or estrogen-like drugs (for women with suspected pregnancy, serum or urine human chorionic gonadotropin test must be negative before enrollment).
  • Any other condition deemed by the investigator to be inappropriate for study participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,172 participants (estimated)

Study arms

  • Experimental
    Aspirin Monotherapy

    Aspirin 75-100 mg orally once daily for 12 months

    Drug: Aspirin

  • Active comparator
    Standard Therapy

    Warfarin (INR 2-3) for 6 months, followed by Aspirin 75-100 mg once daily for 6 months

    Drug: Aspirin · Drug: Warfarin

Interventions

  • Aspirin 75-100 mg orally once daily

  • Warfarin orally with dose adjusted to maintain INR 2-3

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Non-hierarchical Composite Endpoint

    The primary endpoint is a non-hierarchical composite endpoint including all-cause death, stroke, prosthetic valve thrombosis, intracardiac thrombosis, myocardial infarction, deep vein thrombosis or pulmonary embolism, systemic embolism, and life-threatening, disabling, or major bleeding (VARC-3 definition).

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Number of Participants Who Experienced Composite Endpoint of All-Cause Death, Ischemic Stroke, Valve/Intracardiac Thrombosis, and Myocardial Infarction.

    The first key secondary endpoint is composite of all-cause death, ischemic stroke, valve/intracardiac thrombosis, and myocardial infarction.

    Time frame: 12 months post-procedure

  2. Number of Participants Who Experienced Composite of Life-threatening, Disabling, or Major Bleeding (based on VARC-3 criteria Type 2-4)

    Life-threatening or disabling bleeding Fatal bleeding OR Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery OR Overt source of bleeding with drop in haemoglobin of ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 unitsa Major bleeding Overt bleeding either associated with a drop in the haemoglobin level of at least 3.0 g/dL or requiring transfusion of two or three units of whole blood/RBC AND Does not meet criteria of life-threatening or disabling bleeding

    Time frame: 12 months post-procedure

  3. Number of Participants Who Experience Composite of Cardiovascular Death, Major Bleeding, Stroke, and Myocardial Infarction

    Time frame: 12 months post-procedure

  4. Number of Participants Who Experience Clinical Efficacy Composite Endpoint

    Composite endpoint requiring all of the following: freedom from all-cause death; freedom from all stroke; no hospitalization for valve-related or procedure-related reasons; and KCCQ overall score ≥45 with no more than a 10-point decrease from baseline.

    Time frame: 12 months post-procedure

  5. Number of Participants Who Experienced All-Cause Death

    Time frame: 12 months post-procedure

  6. Number of Participants Who Experience Clinically Significant Prosthetic Valve Thrombosis (VARC-3)

    Based on VARC-3 criteria, clinically significant prosthetic valve thrombosis defined as clinical. sequelae of a thromboembolic event (e.g. stroke, TIA, retinal occlusion, other evidence of systemic thromboembolism) or worsening valve stenosis/ regurgitation (e.g. signs of heart failure, syncope) and Haemodynamic valve deterioration Stage 2 or 3 or Confirmatory imaging (CT evidence of HALT or TEE findings) In the absence of clinical sequelae, both Haemodynamic valve deterioration Stage 3 and Confirmatory imaging (CT evidence of HALT or TEE findings)

    Time frame: At 6 months and 12 months post-procedure

  7. Number of Participants Who Experience Bioprosthetic Valve Deterioration Stage 3 by Echocardiography (VARC-3)

    Bioprosthetic Valve Failure Stage 3 defined as increase in mean transvalvular gradient ≥20 mmHg resulting in mean gradient ≥30 mmHg with concomitant decrease in EOA ≥0.6 cm2 or ≥50% and/or decrease in Doppler velocity index ≥0.2 or ≥40% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence, or increase of ≥2grades, of intraprosthetic AR resulting in severe AR

    Time frame: 12 months post-procedure

  8. Number of Participants Who Experience Hypo-Attenuated Leaflet Thickening (HALT) by CT

    Time frame: 12 months post-procedure

  9. Number of Participants Who Experienced Non-Procedure-Related Life-Threatening or Disabling Bleeding (VARC-3)

    Time frame: At 30 days and 12 months post-procedure

  10. Number of Participants Who Experienced Major Bleeding

    Based on VARC 2 criteria

    Time frame: At 30 days and 12 months post-procedure

  11. Number of Participants Who Experienced Minor Bleeding

    Based on VARC 2 criteria

    Time frame: At 30 days and 12 months post-procedure

  12. Number of Participants Who Experienced Aortic Valve Re-Intervention

    Time frame: 12 months post-procedure

  13. Number of Participants Who Experienced Heart Failure Re-Hospitalization

    Time frame: 12 months post-procedure

  14. Number of Participants Who Experienced Infective Endocarditis

    Infective Endocarditis defined as: Meeting at least one of the following criteria: Fulfills the Duke criteria for endocarditis; Intraoperative evidence of an abscess, pus, or vegetation secondary to infection, confirmed by histology or microbiology; Autopsy evidence of an abscess, pus, or vegetation.

    Time frame: 12 months post-procedure

  15. Number of Participants Who Experienced Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    MACCE including cardiac death, aortic valve reintervention, stroke, myocardial infarction, heart failure readmission and life-threatening, disabling, or major bleeding.

    Time frame: At 30 days and 12 months post-procedure

  16. Number of Participants Who Experienced NYHA Class Improvement

    Time frame: At 30 days and 12 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 35 months after the start.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 30, 2026
StartActual
Jul 18, 2026
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2030
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07677410
Collaborators
Suzhou Jiecheng Medical Technology Co., Ltd.
Responsible party
Wei Lai, MD (Principal Investigator, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Jun 30, 2026
Start date
Jul 18, 2026
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Aug 10, 2026

Study contacts

Lai Wei, MD
Contact
Wei.lai@zs-hospital.sh.cn
+86-021-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion